<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21426" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Exchange Transfusion</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hall</surname>
            <given-names>Christopher P.</given-names>
          </name>
          <aff>Michigan State University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lightfoot</surname>
            <given-names>John K.</given-names>
          </name>
          <aff>SUNY Upstate Medical University, Syracuse, New York</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christopher Hall declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John Lightfoot declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21426.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Therapeutic plasma exchange (TPE) is a procedure employed to "cleanse" the blood of various pathologic entities including antibodies, immune complexes, cellular elements, infectious agents, and toxins. A variety of conditions are responsive to therapy with TPE either as a first-line intervention or adjunct therapy. TPE, or plasmapheresis, consists of the separation of whole blood into its liquid and cellular components via centrifugal or membrane-filter technique followed by reintroduction of albumin and/or donor plasma tp the cellular components and re-infusion. This activity reviews the process of TPE, the evaluation and treatment of conditions responsive to therapeutic plasma exchange, and the role of an interprofessional team performing this interventional therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the mechanistic process of therapeutic plasma exchange.</p></list-item><list-item><p>Summarize common conditions responsive to therapeutic plasma exchange.</p></list-item><list-item><p>Describe the mechanism(s) by which therapeutic plasma exchange accomplishes treatment of said conditions.</p></list-item><list-item><p>List the common complications associated with exchange transfusions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21426&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21426">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21426.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Therapeutic plasma exchange (TPE) is a procedure in which blood or&#x000a0;plasma is separated, removed, and replaced with a colloid solution of either albumin and/or donor plasma so as to accomplish the elimination of a pathologic entity.&#x000a0; Plasma is exchanged in volumes, usually between&#x000a0;1&#x000a0;to 1.5 L to remove dysfunctional cells, autoantibodies, immune complexes, cellular byproducts, parasites/bacteria, and toxins. &#x000a0;There are two different methods for plasma separation&#x000a0;- manual and automated.</p>
        <p>The manual method consists of phlebotomizing a patient, centrifuging the blood to separate plasma from cellular components, extracting the plasma, and then returning the cellular components back to the patient. The automated method involves the use of a plasmapheresis machine, which accomplishes the same functions as the manual method in a&#x000a0;continuous flow extracorporeal circuit.&#x000a0;The removal and replacement of plasma cause an overall dilution for which one volume exchange clears 66% of target constituents and 85% with a second and 93% with a third.&#x000a0; The efficiency of TPE in eliminating the undesired entity&#x000a0;is dependent on mass, production rate, and location in the blood (intracellular vs. extracellular)&#x000a0;of said&#x000a0;entity.<xref ref-type="bibr" rid="article-21426.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21426.s3" sec-type="Indications">
        <title>Indications</title>
        <p>The American Society for Apheresis guidelines, Eight Edition, published in 2019, includes a periodically updated lengthy list of diseases with indications for TPE alone or along with other therapies.&#x000a0; It serves as&#x000a0;a reference for TPE management of diseases, thoroughly detailing rationale, impact, technical issues, therapeutic plan, clinical/laboratory endpoints, and timing/location.<xref ref-type="bibr" rid="article-21426.r2">[2]</xref>&#x000a0; This summary is not nearly as inclusive or comprehensive&#x000a0;as that reference, however, below are the most commonly encountered indications.</p>
        <p><bold>Sickle cell disease</bold> is an autosomal recessive group of inherited disorders&#x000a0;affecting the production of the&#x000a0;beta-globin subunits of hemoglobin.&#x000a0; Under episodes of physical insult (ie: hypo/hyperthermia, dehydration, emotion stress, hypoxia, etc) the red blood cells transform into a rigid sickled shape that does not easily&#x000a0;traverse&#x000a0;the vasculature. Sickle cells have abnormally short lifespans resulting in anemia in the affected individual. Additionally, patients suffering from sickle cell disease are also predisposed to certain bacterial infections&#x000a0;and&#x000a0;painful vaso-occlusive events known as sickle cell crisis, stroke, and death in addition to other comorbidities.&#x000a0;Therapeutic plasma exchange is indicated for severe anemia and multiorgan failure.&#x000a0; The objective is to decrease vaso-occlusion by lowering the sickle hemoglobin to below 30% and raising the hemoglobin oxygen saturation. &#x000a0;At least one study has demonstrated that TPE has synergistic effects with red cell exchange therapy in patients with multi-organ failure.<xref ref-type="bibr" rid="article-21426.r3">[3]</xref>&#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Neonatal polycythemia</bold> is a neonatal condition whereby&#x000a0;hematocrit (Hct) measures &#x0003e;65%&#x000a0;in an infant born at term. It results from&#x000a0;chromosomal anomalies, twin to twin transfusion syndrome, or growth restriction in the womb.&#x000a0; These infants are at risk of hyperviscosity and may develop symptoms of hypoglycemia, cyanosis, and apnea if not quickly managed with intravenous hydration.&#x000a0; Therapeutic plasma exchange is indicated for progressive symptoms refractory to initial treatment.&#x000a0; This must be initiated quickly as Hct peaks a few hours after birth.&#x000a0; In a systematic review and meta-analysis, it was found that crystalloid was as effective as a colloid in managing hematologic state by use of partial exchange transfusion.<xref ref-type="bibr" rid="article-21426.r4">[4]</xref></p>
        <p><bold>Neonatal hyperbilirubinemia</bold> occurs when a neonatal born &#x0003e;35 weeks has a total bilirubin (TB) &#x0003e;25 mg/dL.&#x000a0; The causes are either physiologic (transient period of mismatched increased red blood cell production and bilirubin metabolism) or pathologic (a number of disease states involving immune-mediated hemolysis).&#x000a0; These infants are at risk for brain injury from bilirubin-induced neurologic dysfunction in which bilirubin crosses the blood-brain barrier and builds up within the tissue.&#x000a0; Phototherapy (PT) with ultraviolet light is the mainstay of therapy, however, TPE is indicated for&#x000a0;persistently&#x000a0;elevated TB levels despite PT. &#x000a0;Double-volume exchange transfusion will remove about 50% to 75% of TB from pre-exchange value. &#x000a0;Triple-volume exchange removes approximately&#x000a0;95% of TB but is rarely&#x000a0;required. &#x000a0;Due to the prohibitive cost of even more advanced therapies such as intrauterine transfusion and immunoglobulin therapy,&#x000a0;TPE is the primary&#x000a0;alternative to phototherapy in the management of&#x000a0;severe hyperbilirubinemia in the developing world.<xref ref-type="bibr" rid="article-21426.r5">[5]</xref></p>
        <p><bold>Babesiosis</bold> is a disease caused by the parasite <italic toggle="yes">Babesia microti</italic>. It is carried and transmitted by the deer tick, Ixodes scapularis, and&#x000a0;may also result from&#x000a0;transmission from infected mother to fetus or infected blood product transfusion. &#x000a0;The parasite infects, replicates within, and destroys red blood cells resulting in&#x000a0;hemolytic anemia and flu-like symptoms. The treatment regimen of&#x000a0;atovaquone&#x000a0;and&#x000a0;azithromycin&#x000a0;is often used for uncomplicated cases.&#x000a0; Severe cases involving end-organ damage (respiratory distress, sepsis, etc) may benefit from therapeutic plasma exchange - reducing parasite burden, correcting anemia, and removing inflammatory mediators and toxic by-products.<xref ref-type="bibr" rid="article-21426.r6">[6]</xref></p>
        <p><bold>Guillain-Barre syndrome (GBS)</bold>, or acute inflammatory demyelinating polyradiculoneuropathy, is an acute immune-mediated disorder targeting the myelin&#x000a0;of the peripheral nervous system.&#x000a0; This is usually incited by antecedent&#x000a0;bacterial or viral infections of the gastrointestinal or respiratory tract.&#x000a0; Initially, symptoms are numbness and weakness bilaterally starting in the distal extremities and progressing proximally. &#x000a0;GBS can become life-threatening if innervation of the cardiac and pulmonary systems is involved, or when severe chest wall skeletal muscle weakness develops.&#x000a0; Treatment is supportive measures along with intravenous immunoglobulins and TPE for severe cases.&#x000a0; The acute phase reactant, plasma fibrinogen, is elevated in acute GBS and its level is&#x000a0;inversely&#x000a0;related to treatment success.&#x000a0; Treatment with TPE is conducted&#x000a0;until a continuous 30% decrease in plasma fibrinogen is observed.<xref ref-type="bibr" rid="article-21426.r7">[7]</xref></p>
        <p><bold>Myasthenia gravis (MG)</bold> is an autoimmune disease characterized by chronic bilateral skeletal muscle weakness,&#x000a0;particularly the ocular, oral, and facial muscles. Significant extremity weakness and respiratory muscle paralysis are usually&#x000a0;affected only in cases of myasthenic crisis. &#x000a0;MG&#x000a0;is caused by antibodies to the acetylcholinesterase&#x000a0;(Ach)&#x000a0;receptor at the terminal endplate of the neuromuscular junction. The consequence of diminished Ach activity due to inhibited and reduced Ach receptors accounts for the clinical presentation.&#x000a0; Treatment typically involves Ach&#x000a0;inhibitors and immunosuppressants.&#x000a0; TPE removal of acetylcholine receptor antibodies is indicated for severe exacerbations involving bulbar dysfunction and/or respiratory compromise. &#x000a0;Treatment goals are short-term improvement in skeletal muscle strength and motor performance (neuromuscular junction transmission) as well as&#x000a0;improvement in respiratory function.<xref ref-type="bibr" rid="article-21426.r8">[8]</xref></p>
        <p><bold>Heparin-induced thrombocytopenia (HIT</bold>) is an anti-platelet antibody-mediated condition resulting in thrombocytopenia and thrombophilia. Heparin bound to the chemokine,&#x000a0;platelet factor 4 (PF4), elicits an immune response directed against this structure. &#x000a0;The resulting complex of IgG, PF4, and heparin bind with and further activate platelets causing thrombi and thrombocytopenia.&#x000a0;Initial treatment involves discontinuation of&#x000a0;heparin.&#x000a0; Therapeutic plasma exchange is indicated in severe or persistent cases to remove such&#x000a0;"HIT complexes". A recent international practice survey revealed cardiovascular surgery followed by HIT-associated thrombosis as the&#x000a0;most common reason to prophylactically treat re-exposures in patients requiring heparin.&#x000a0; The fluid replaced was often plasma and the occurrences of treatment were laboratory/clinical response-dependent.<xref ref-type="bibr" rid="article-21426.r9">[9]</xref></p>
        <p><bold>Thrombotic thrombocytopenic purpura (TTP)</bold> is an autoantibody-mediated condition characterized by thrombophilia and thrombocytopenia. Often idiopathic, TTP's mortality rate exceeds&#x000a0;90%, untreated. Antibodies crossreact&#x000a0;against&#x000a0;the ADAMTS13 enzyme, which catalyzes the degradation of&#x000a0;von Willebrand factor (vWF). &#x000a0;When ADAMTS13 is inhibited, vWF's action is unopposed and thrombophilia results.&#x000a0; Symptoms include diffuse ecchymosis and petechiae, jaundice, fever, weakness, headaches, confusion, tachycardia, and tachypnea. &#x000a0;TPE is employed to remove&#x000a0;IgG and resupply&#x000a0;with functional ADAMTS13. Plasma exchange is more effective than plasma infusion.<xref ref-type="bibr" rid="article-21426.r10">[10]</xref>&#x000a0; TPE is conducted&#x000a0;daily until levels of lactate dehydrogenase (which increases in thrombophilic conditions) and platelets normalize.&#x000a0;</p>
        <p><bold>Goodpasture syndrome (GPS)</bold> or anti-glomerular basement membrane disease is an idiopathic, autoimmune disease directed against&#x000a0;the basement membrane (alpha-3-subunit of type IV collagen) in&#x000a0;tissues unique to lungs and kidneys. Symptoms typically consist of&#x000a0;chest pain, shortness of breath, hemoptysis, and hematuria. Mortality is high without proper diagnosis and intervention.&#x000a0; Treatment with immunosuppressants and TPE&#x000a0;reduces renal and pulmonary injury and provides symptom relief. The anti-GBMs promptly decrease with TPE and immunosuppression, thus serving as an effective marker to guide ongoing therapy.<xref ref-type="bibr" rid="article-21426.r11">[11]</xref></p>
        <p><bold>Renal transplant</bold> is yet another application of&#x000a0;TPE. It&#x000a0;is indicated prior to, during, and after transplantation. TPE&#x000a0;aids in the desensitization of the immune system and to remove antibodies that damage renal vasculature following transplant and potentially result in rejection.<xref ref-type="bibr" rid="article-21426.r12">[12]</xref>&#x000a0;&#x000a0;</p>
        <p><bold>Malaria</bold> is a disease caused by several&#x000a0;species&#x000a0;of the Plasmodium parasite,&#x000a0;typically transmitted&#x000a0;via the Anopheles mosquito. Once in the bloodstream the parasite infects and destroys liver cells and red blood cells.&#x000a0; Severe flu-like symptoms of fluctuating shivers and sweats, diffuse body pain, and weakness accompanied by jaundice and respiratory distress are the disease hallmarks. Death is not uncommon. Treatment with antimalarial medications (often artemisinin-combination therapy) is typically effective in uncomplicated cases.&#x000a0; Though not endorsed by the World Health Organization or the United States Centers for Disease Control and Prevention, TPE is occasionally used.&#x000a0; One retrospective study found mixed results with TPE in observed physiologic improvements (liver functions and inflammatory markers) but no improvement in parasite burden or disease state.<xref ref-type="bibr" rid="article-21426.r13">[13]</xref></p>
      </sec>
      <sec id="article-21426.s4" sec-type="Equipment">
        <title>Equipment</title>
        <p>Intravenous access (needles, catheters, tubing, etc) for two sites on the body, centrifuge (speeds of 2000-2500 rpm), or plasma separation filter (60&#x000a0;to 900 kDa = albumin to IgM), anticoagulant (citrate or heparin), and replacement fluid (albumin or fresh frozen plasma).<xref ref-type="bibr" rid="article-21426.r1">[1]</xref></p>
      </sec>
      <sec id="article-21426.s5" sec-type="Personnel">
        <title>Personnel</title>
        <p>The individuals necessary for the performance of TPE&#x000a0;are the pheresis technician, pathologist, and hematologist beyond the treating physician. Contact and communication between these individuals are vital to the expeditious treatment of each patient.</p>
      </sec>
      <sec id="article-21426.s6" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p><bold>Centrifugal therapeutic plasma exchange:</bold> A continuous flow extracorporeal circuit is formed from the patient to the centrifuge and back to the patient. Citrate (anticoagulant) is added to the blood flow of 10-150 ml/min, while centrifugal forces separate and sieve off plasma from the heavier (white and red cells) of blood.&#x000a0; A replacement fluid (albumin and/or fresh frozen plasma) is recombined with the blood and returned to the patient.<xref ref-type="bibr" rid="article-21426.r1">[1]</xref></p>
        <p><bold>Membrane therapeutic plasma exchange:</bold> A continuous flow extracorporeal circuit is formed from the patient to the filter-membrane and back to the patient. Heparin (anticoagulant) is added to the blood flow of 150 ml/min while membrane ultrafiltration properties of pore size and distribution separate and sieve off plasma from the heavier (white and red cells) of blood.&#x000a0; A replacement fluid (albumin and/or fresh frozen plasma) is recombined with the blood and returned to the patient.<xref ref-type="bibr" rid="article-21426.r1">[1]</xref></p>
      </sec>
      <sec id="article-21426.s7" sec-type="Complications">
        <title>Complications</title>
        <p>Risks include infection, hemorrhage, thromboembolism, and death from the procedure itself with anaphylactic, allergic, and hemolytic reactions occurring more likely from plasma or blood transfusion.&#x000a0; A recent retrospective cohort study of 1201 therapeutic plasma exchange procedures in 435 children found pruritus/urticaria (7%), hypertension (1.92%), and hypotension (1.17%) to be the most common complications.&#x000a0; There were severe complications (cryptococcosis neoformans, anaphylactic shock, and toxic epidermal necrolysis) in 5 patients (0.42%) following TPE procedures.<xref ref-type="bibr" rid="article-21426.r14">[14]</xref></p>
      </sec>
      <sec id="article-21426.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Therapeutic plasma exchange is a useful procedure to eliminate from circulation the particular&#x000a0;pathologic entity.&#x000a0; It is normally reserved as a treatment adjunct or when initial therapies have failed. The Journal of Clinical Apheresis produces guidelines on the use of Apheresis in clinical practice. This is an evidence-based guide to a vast collection of diseases requiring this treatment.&#x000a0; Per disease and the state of the patient, this guide helps determine when TPE is appropriate and what the expected end results. &#x000a0;Coordination of care amongst the various healthcare personnel&#x000a0;is required to ensure&#x000a0;patient safety, the propriety of therapy in each particular situation, and application of alternative and/or adjunct therapies indicated for a particular patient.<xref ref-type="bibr" rid="article-21426.r2">[2]</xref></p>
      </sec>
      <sec id="article-21426.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dialogue amongst the involved&#x000a0;physicians, nursing staff, and laboratory technicians are vital to identify the availability of TPE at any particular institution and to subsequently make appropriate transitions for patients requiring TPE when not available in the initial&#x000a0;facility. In situations when TPE is not emergency indicated, the arrangement of outpatient care will be required. Coordination of effort between the health professionals to enhance patient-centered care and outcomes is a top priority.&#x000a0; They need to recognize who will require therapeutic plasma exchange and when to initiate it.&#x000a0;</p>
        <p>The diseases that require this treatment are rare, of various etiologies (genetic, physiologic, infectious, autoimmune), and are often initially managed with supportive therapies (supplemental oxygen, intravenous hydration, immunosuppressants, phototherapy).&#x000a0; Appropriate treatment and selection of patients and timing of intervention all need to be clearly communicated within and between medical professionals caring for the patient.</p>
      </sec>
      <sec id="article-21426.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21426&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21426">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21426/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21426">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21426.s11">
        <fig id="article-21426.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Nomogram for Exchange Transfusions in Newborns. Similar to phototherapy, the exchange transfusion threshold is guided by a nomogram. Contributed by R Kabir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kabir_Nomogram__for__exchange__transfusions" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21426.s12">
        <title>References</title>
        <ref id="article-21426.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Balogun</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Principles of separation: indications and therapeutic targets for plasma exchange.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>181</fpage>
            <page-range>181-90</page-range>
            <pub-id pub-id-type="pmid">24178973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padmanabhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Connelly-Smith</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aqui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Balogun</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Klingel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Schneiderman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zantek</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Dunbar</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>GEJ</given-names>
              </name>
            </person-group>
            <article-title>Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.</article-title>
            <source>J Clin Apher</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-354</page-range>
            <pub-id pub-id-type="pmid">31180581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boga</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kozanoglu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ozdogu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozyurek</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Plasma exchange in critically ill patients with sickle cell disease.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-22</page-range>
            <pub-id pub-id-type="pmid">17707694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dempsey</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Barrington</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Crystalloid or colloid for partial exchange transfusion in neonatal polycythemia: a systematic review and meta-analysis.</article-title>
            <source>Acta Paediatr</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>94</volume>
            <issue>11</issue>
            <fpage>1650</fpage>
            <page-range>1650-5</page-range>
            <pub-id pub-id-type="pmid">16303705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malla</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poudyal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sathian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Malla</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>A Prospective Study on Exchange Transfusion in Neonatal Unconjugated Hyperbilirubinemia--in a Tertiary Care Hospital, Nepal.</article-title>
            <source>Kathmandu Univ Med J (KUMJ)</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>13</volume>
            <issue>50</issue>
            <fpage>102</fpage>
            <page-range>102-8</page-range>
            <pub-id pub-id-type="pmid">26643826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saifee</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?</article-title>
            <source>J Clin Apher</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>454</fpage>
            <page-range>454-8</page-range>
            <pub-id pub-id-type="pmid">26481763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanjay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sodano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gorson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Ropper</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barr&#x000e9; syndrome.</article-title>
            <source>J Clin Apher</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-10</page-range>
            <pub-id pub-id-type="pmid">16342192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Birinder</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange in the treatment of myasthenia gravis.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-13</page-range>
            <pub-id pub-id-type="pmid">25624644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onwuemene</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Zantek</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Rollins-Raval</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Raval</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ipe</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Kuchibhatla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ECC</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey.</article-title>
            <source>J Clin Apher</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>545</fpage>
            <page-range>545-554</page-range>
            <pub-id pub-id-type="pmid">31116461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rock</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Shumak</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Buskard</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Blanchette</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Spasoff</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1991</year>
            <month>Aug</month>
            <day>08</day>
            <volume>325</volume>
            <issue>6</issue>
            <fpage>393</fpage>
            <page-range>393-7</page-range>
            <pub-id pub-id-type="pmid">2062330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.</article-title>
            <source>Ann Intern Med</source>
            <year>2001</year>
            <month>Jun</month>
            <day>05</day>
            <volume>134</volume>
            <issue>11</issue>
            <fpage>1033</fpage>
            <page-range>1033-42</page-range>
            <pub-id pub-id-type="pmid">11388816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ridel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kissling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mesnard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hertig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rondeau</surname>
                <given-names>&#x000c9;</given-names>
              </name>
            </person-group>
            <article-title>[Plasma exchange in nephrology: Indications and technique].</article-title>
            <source>Nephrol Ther</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-55</page-range>
            <pub-id pub-id-type="pmid">28110970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Manual exchange transfusion for severe imported falciparum malaria: a retrospective study.</article-title>
            <source>Malar J</source>
            <year>2018</year>
            <month>Jan</month>
            <day>16</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">29338720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Complications of therapeutic plasma exchange: A retrospective study of 1201 procedures in 435 children.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>98</volume>
            <issue>50</issue>
            <fpage>e18308</fpage>
            <pub-id pub-id-type="pmid">31852113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21426.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Almeyda-Alejo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tumin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Redpath</surname>
                <given-names>NSJ</given-names>
              </name>
              <name>
                <surname>Guillen-Hernandez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Three or four doses of intravenous immunoglobulin G treatment for isoimmune hemolytic disease: A case series and literature review.</article-title>
            <source>J Neonatal Perinatal Med</source>
            <year>2024</year>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <page-range>153-158</page-range>
            <pub-id pub-id-type="pmid">38143377</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
